Letztes “update” :
08/05/2024
Infostab
Molekülverzeichnis
Zusammenfassende Listen
Suche nach kompatibilitäten
Y-Kompatibilitätstabelle
Literaturverzeichnis
Forschungsgruppen
Valistab
Poster
Links
Sponsoren
Autoren
Hinweise fûr den Benutzer
Newsletter
Hydrochlorothiazide
Chemische Struktur
Literaturverzeichnis : Hydrochlorothiazide
Typ
Veröffentlichung
2435
Zeitung
Allen LV, Jr, Erickson MA,
Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids
Am J Health-Syst Pharm 1996 ; 53: 2304-2309.
3361
Zeitung
Santovena A, Hernandez-Paiz Z, Farina J.B.
Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide.
Int J Pharm 2012 ; 423: 360-364.
3399
Poster
Li Y.Y, Postma D.J, Wagenaar H.W.G.
Development of a hydrochlorothiazide 0.5 mg/mL oral solution for children.
EAHP Congress Paris 2013
3910
Zeitung
Polonini H.C, Silva S .L, de Almeida T.R, Brand?o M.A, Ferreira A.O.
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions.
EJHP 2016 ; 23: 352-358.
4177
Zeitung
Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526
4198
Zeitung
Uriel M, Gomez-Rincon C, Marro D.
Stability of regularly prescribed oral liquids formulated with SyrSpend® SF.
Pharmazie 2018 73;196-201
4256
Zeitung
Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, Dupuis A.
Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients.
Pharmaceutics 2019 ;11,190:
Mentions Légales
